Literature DB >> 20095840

Fatal respiratory events caused by zanamivir nebulization.

Sumalee Kiatboonsri, Charn Kiatboonsri, Pongdhep Theerawit.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20095840     DOI： 10.1086/650176

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  12 in total

1.  Emerging influenza antiviral resistance threats.

Authors:  Frederick G Hayden; Menno D de Jong
Journal:  J Infect Dis       Date:  2011-01-01       Impact factor: 5.226

2.  Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa.

Authors:  Timothy M Uyeki; Henry H Bernstein; John S Bradley; Janet A Englund; Thomas M File; Alicia M Fry; Stefan Gravenstein; Frederick G Hayden; Scott A Harper; Jon Mark Hirshon; Michael G Ison; B Lynn Johnston; Shandra L Knight; Allison McGeer; Laura E Riley; Cameron R Wolfe; Paul E Alexander; Andrew T Pavia
Journal:  Clin Infect Dis       Date:  2019-03-05       Impact factor: 9.079

Review 3.  Administration of dry powders during respiratory supports.

Authors:  Wei-Ren Ke; Rachel Yoon Kyung Chang; Philip Chi Lip Kwok; Patricia Tang; Lan Chen; Donghao Chen; Hak-Kim Chan
Journal:  Ann Transl Med       Date:  2021-04

Review 4.  Clinical use of approved influenza antivirals: therapy and prophylaxis.

Authors:  Michael G Ison
Journal:  Influenza Other Respir Viruses       Date:  2013-01       Impact factor: 4.380

5.  Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation.

Authors:  Won-Young Kim; Gee Young Suh; Jin Won Huh; Sung-Han Kim; Min-ju Kim; Yun Seong Kim; Hye-Ryoun Kim; Yon Ju Ryu; Min Soo Han; Young Gwan Ko; Gyu Rak Chon; Kwan Ho Lee; Sang-Ho Choi; Sang-Bum Hong
Journal:  Antimicrob Agents Chemother       Date:  2011-10-03       Impact factor: 5.191

6.  Aerosol therapy in intensive and intermediate care units: prospective observation of 2808 critically ill patients.

Authors:  Stephan Ehrmann; Ferran Roche-Campo; Laetitia Bodet-Contentin; Keyvan Razazi; Jonathan Dugernier; Josep Trenado-Alvarez; Alexis Donzeau; François Vermeulen; David Thévoz; Metaxia Papanikolaou; Antoine Edelson; Héctor León Yoshido; Lise Piquilloud; Karim Lakhal; Carlos Lopes; Carlos Vicent; Arnaud Desachy; Gabriela Apiou-Sbirlea; Daniel Isabey; Laurent Brochard
Journal:  Intensive Care Med       Date:  2015-11-24       Impact factor: 17.440

7.  Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection.

Authors:  P L A Fraaij; E van der Vries; M F C Beersma; A Riezebos-Brilman; H G M Niesters; A A van der Eijk; M D de Jong; D Reis Miranda; A M Horrevorts; B U Ridwan; M J H M Wolfhagen; R J Houmes; J T van Dissel; R A M Fouchier; A C M Kroes; M P Koopmans; A D M E Osterhaus; C A B Boucher
Journal:  J Infect Dis       Date:  2011-09-01       Impact factor: 5.226

Review 8.  Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead.

Authors:  Tony Velkov; Nusaibah Abdul Rahim; Qi Tony Zhou; Hak-Kim Chan; Jian Li
Journal:  Adv Drug Deliv Rev       Date:  2014-11-12       Impact factor: 15.470

Review 9.  Severe community-acquired pneumonia.

Authors:  Wendy I Sligl; Thomas J Marrie
Journal:  Crit Care Clin       Date:  2013-07       Impact factor: 3.598

10.  Characteristics and mortality of severe influenza cases treated with parenteral aqueous zanamivir, United Kingdom, October 2009 to January 2011.

Authors:  Paul Robert Cleary; Jonathan Crofts; Frances Parry-Ford; Meera Chand; Nick Phin
Journal:  Influenza Other Respir Viruses       Date:  2018-10-19       Impact factor: 4.380
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.